Insider · CIK 0002000585
Douglas Michael Parker
Files at CLS (CELESTICA INC). First filing Feb 5, 2025, latest Feb 6, 2026.
Douglas Michael Parker files SEC Form 4 as officer at CLS (CELESTICA INC). Since Feb 5, 2025, Douglas Michael Parker has reported 0 open-market buys worth $0 and 3 open-market sells worth $1.4M, the latest filed on Feb 6, 2026.
A track record needs three past buys with six months of prices behind them; Douglas Michael Parker has 0, so none is measured yet.
The newest scored trade: sold $271k of CLS on Feb 4, 2026, filed Feb 6, 2026, scored 48 (moderate). In the last 12 months: 0 buys worth $0 and 2 sells worth $1.1M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CLS: CELESTICA INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | CELESTICA INC | $271k 948 shares | -176% | +317% from low-22% from high | |
| 57Moderate | CELESTICA INC | $782k 2,724 shares | -170% | +331% from low-19% from high | |
| 65Notable | CELESTICA INC | $332k 2,723 shares | -100% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 2, 2026 | CLS CELESTICA INC. | 2,724 0.00% of outstanding | $765k | Feb 2, 2026 | none |
| Feb 3, 2025 | CLS CELESTICA INC | 2,723 0.00% of outstanding | $489k | Feb 3, 2025 | none |
Transactions
Every row this insider has filed, 26 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | CLS CELESTICA INC | MOption exercise Common Shares | +1,159 | $0.00 | $0 | 1,159 | Feb 6, 2026 |
| Feb 4, 2026 | CLS CELESTICA INC | FTax withholding Common Shares | -621 | $286.80 | $178k | 538 | Feb 6, 2026 |
| Feb 4, 2026 | CLS CELESTICA INC | SOpen-market sale Common Shares | -538 | $286.80 | $154k | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CLS CELESTICA INC | MOption exercise Common Shares | +883 | $0.00 | $0 | 883 | Feb 6, 2026 |
| Feb 4, 2026 | CLS CELESTICA INC | FTax withholding Common Shares | -473 | $283.51 | $134k | 410 | Feb 6, 2026 |
| Feb 4, 2026 | CLS CELESTICA INC | SOpen-market sale Common Shares | -410 | $283.51 | $116k | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CLS CELESTICA INC | MOption exercise Restricted Share Unitsderivative | -1,159 | $0.00 | $0 | 1,158 | Feb 6, 2026 |
| Feb 4, 2026 | CLS CELESTICA INC | MOption exercise Restricted Share Unitsderivative | -883 | $0.00 | $0 | 1,765 | Feb 6, 2026 |
| Feb 2, 2026 | CLS CELESTICA INC | MOption exercise Common Shares | +3,449 | $0.00 | $0 | 3,449 | Feb 3, 2026 |
| Feb 2, 2026 | CLS CELESTICA INC | FTax withholding Common Shares | -1,847 | $286.98 | $530k | 1,602 | Feb 3, 2026 |
| Feb 2, 2026 | CLS CELESTICA INC | SOpen-market sale Common Shares | -1,602 | $286.98 | $460k | 0 | Feb 3, 2026 |
| Feb 2, 2026 | CLS CELESTICA INC | MOption exercise Common Shares | +2,415 | $0.00 | $0 | 2,415 | Feb 3, 2026 |
| Feb 2, 2026 | CLS CELESTICA INC | FTax withholding Common Shares | -1,293 | $286.98 | $371k | 1,122 | Feb 3, 2026 |
| Feb 2, 2026 | CLS CELESTICA INC | SOpen-market sale Common Shares | -1,122 | $286.98 | $322k | 0 | Feb 3, 2026 |
| Feb 2, 2026 | CLS CELESTICA INC | MOption exercise Restricted Share Unitsderivative | -3,449 | $0.00 | $0 | 3,449 | Feb 3, 2026 |
| Feb 2, 2026 | CLS CELESTICA INC | MOption exercise Restricted Share Unitsderivative | -2,415 | $0.00 | $0 | 2,414 | Feb 3, 2026 |
| Feb 3, 2026 | CLS CELESTICA INC | AGrant or award Restricted Share Unitsderivative | +1,544 | $0.00 | $0 | 1,544 | Feb 3, 2026 |
| Feb 4, 2025 | CLS CELESTICA INC | AGrant or award Restricted Share Unitsderivative | +2,317 | $0.00 | $0 | 2,317 | Dec 4, 2025 |
| Feb 3, 2025 | CLS CELESTICA INC | SOpen-market sale Common Shares | -2,723 | $122.05 | $332k | 0 | Feb 5, 2025 |
| Feb 4, 2025 | CLS CELESTICA INC | AGrant or award Restricted Share Unitsderivative | +2,648 | $0.00 | $0 | 2,648 | Feb 5, 2025 |
| Feb 3, 2025 | CLS CELESTICA INC | MOption exercise Common Shares | +3,449 | $0.00 | $0 | 3,449 | Feb 3, 2025 |
| Feb 3, 2025 | CLS CELESTICA INC | FTax withholding Common Shares | -1,847 | $123.88 | $229k | 1,602 | Feb 3, 2025 |
| Feb 3, 2025 | CLS CELESTICA INC | MOption exercise Common Shares | +2,414 | $0.00 | $0 | 4,016 | Feb 3, 2025 |
| Feb 3, 2025 | CLS CELESTICA INC | FTax withholding Common Shares | -1,293 | $123.88 | $160k | 2,723 | Feb 3, 2025 |
| Feb 3, 2025 | CLS CELESTICA INC | MOption exercise Restricted Share Unitsderivative | -3,449 | $0.00 | $0 | 6,898 | Feb 3, 2025 |
| Feb 3, 2025 | CLS CELESTICA INC | MOption exercise Restricted Share Unitsderivative | -2,414 | $0.00 | $0 | 4,829 | Feb 3, 2025 |
Questions about Douglas Michael Parker
Answered from the filings on this page, as of the latest one.
Is Douglas Michael Parker buying or selling?
In the last 12 months Douglas Michael Parker reported 0 open-market buys worth $0 and 2 open-market sells worth $1.1M on SEC Form 4; the latest was sold $271k of CLS on Feb 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Douglas Michael Parker's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Douglas Michael Parker has 0.
Where does Douglas Michael Parker file Form 4?
Douglas Michael Parker has filed Form 4 at CLS (CELESTICA INC) as Chief Legal Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.